[Erythropoietin resistance as initial presentation of ANCA-positive intra-alveolar hemorrhage in a hemodialysis patient].
Sirvent
A E
AE
Arenas
M D
MD
Egea
J J
JJ
Gil
M T
MT
D000368:Aged; D000740:Anemia / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood*; D004921:Erythropoietin / Q000008:administration & dosage; D005260:Female; D006470:Hemorrhage / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008171:Lung Diseases / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D011650:Pulmonary Alveoli / Q000098:blood supply / Q000473:pathology*; D006435:Renal Dialysis; D016896:Treatment Outcome
D019268:Antibodies, Antineutrophil Cytoplasmic; D007166:Immunosuppressive Agents; D004921:Erythropoietin